BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,405,000 | -64.8% | 84,250 | +2.3% | 0.83% | -66.0% |
| Q3 2021 | $3,990,000 | -15.4% | 82,350 | +6.5% | 2.45% | -22.3% |
| Q2 2021 | $4,715,000 | -0.5% | 77,350 | +0.6% | 3.16% | +4.8% |
| Q1 2021 | $4,737,000 | -13.4% | 76,900 | 0.0% | 3.01% | -12.8% |
| Q4 2020 | $5,468,000 | +98.5% | 76,900 | +4.7% | 3.45% | +61.8% |
| Q3 2020 | $2,754,000 | +13.5% | 73,425 | -1.3% | 2.14% | +2.4% |
| Q2 2020 | $2,427,000 | +142.5% | 74,425 | +115.7% | 2.08% | +111.8% |
| Q1 2020 | $1,001,000 | -17.2% | 34,500 | 0.0% | 0.98% | -0.2% |
| Q4 2019 | $1,209,000 | +139.9% | 34,500 | +46.8% | 0.99% | +93.7% |
| Q3 2019 | $504,000 | – | 23,500 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |